Merck Sharp + Dohme Corp.

Genentech, Inc.

Merck + Co., Inc.

Merck Sharpe & Dohme Corp.

Chdi Foundation, Inc.

Neumora Therapeutics, Inc.

Calliditas Therapeutics Suisse Sa

F. Hoffmann-la Roche Ag

Mark Stewart Chambers

Philip Jones

Zachary Kevin Sweeney

Angus Murray MacLeod

Anthony A Estrada

Bryan K Chan

Charles Baker-Glenn

Robert James Maxey

Leslie Joseph Street

Huifen Chen

David James Hallett

Victor G Matassa

Helen Jane Szekeres

Tamara Ladduwahetty

Stephen Robert Fletcher

Daniel J Burdick

Simon Charles Goodacre

Sander G Mills

Timothy Harrison

Jose Luis Castro Pineiro

Shrenik K Shah

Brian John Williams

Paul E Finke

Conrad P Dorn

Jeffrey John Hale

Daniel Shore

Sarah Christine Hobbs

Michael Geoffrey Neil Russell

Helen Jane Bryant

Malcolm MacCoss

William Robert Carling

Richard Thomas Lewis

Neil Roy Curtis

Kevin William Moore

Guiling Zhao

Shumei Wang

Michela Bettati

Daniel Jon Burdick

Janet L Gunzner-Toste

Howard Barff Broughton

Andrew S Jennings

David C Billington

Mark G Bock

Robert M Jones

Celia Dominguez

Raymond Baker

Ian James Collins

Longbin Liu

Malcolm Maccoss

Wesley Peter Blackaby

Alan Findlay Haughan

Martin Richard Teall

Karine Fabienne Malagu

Kevin John Merchant

Peter J Machin

Graham A Showell

Grant Wishart

Chris Knight

Austin John Reeve

Andrew J Stott

Mariangela Urbano

Michael Geoffrey Russell

Gary Brandt

David Hardick

Peter Alan Hunt

Peter Blurton

Linda Elizabeth Keown

Alexander Charles Humphries

Jason Tierney

Myra Gilligan

Sylvain Celanire

Chris Lock

Freddy Heitz

Janet Gunzner-Tate

Nikolay V Plotnikov

Huw Vater

William Esmieu

Benjamin Perry

Andrew Sharpe

Alastair Hodges

Brett Cosgrove

Jonathan Spencer

Cole Clissold

Emanuela Gancia

Monique Bodil Van Neil

Leslie Jospeh Street

Janet Gunzner-Toste

Daniel John Burdick

David Shore

Provided herein are certain compounds useful as HTT modulators. Such compound are useful in the treatment of Huntington's disease.

HTT modulators for treating Huntington's disease

Disclosed herein are new compounds, pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).

Compounds as NADPH oxidase inhibitors

Compounds are provided that antagonize vasopressin receptors, particularly the V1a receptor products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof: wherein Q, Q, Q, R, R, Rand X are as defined herein.

Vasopressin receptor antagonists and products and methods related thereto

Pyrazole compounds that are modulators of LRRK2, methods of making the compounds, and methods for using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.

Pyrazole aminopyrimidine derivatives as LRRK2 modulators

Compounds of the formula I: or pharmaceutically acceptable salts thereof,wherein m, n. X, R, R, R, Rand Rare as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.

Aminopyrimidine derivatives as LRRK2 modulators

Compounds of the formula I: or pharmaceutically acceptable salts thereof,

Compounds of the formula I: or pharmaceutically acceptable salts thereof,wherein A, X, R, R, Rand Rare as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.

Compounds of the formula I: or pharmaceutically acceptable salts thereof,wherein m, n. X, R, R, R, R, Rand Rare as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.

Aminopyrimidine derivatives as LRRK2 inhibitors

Compounds of formula (I) are potent and selective 5-HTantagonists, useful in treatment of a variety of adverse conditions of the CNS. 

[object Object]

The present invention discloses a compound of formula (I): wherein: Ris an aryl or heteroaryl ring; Ris hydroxy, Calkoxy, Calkyl, amino, NR'R&#x2033; or Calkyl-NR&#x2032;R&#x2033; where R&#x2032; and R&#x2033; are independently chosen from hydrogen and Calkyl and where R&#x2032; and R&#x2033;, together with the nitrogen atom to which they are attached, form a saturated nitrogen-containing 3-7 membered heterocycle optionally containing a further nitrogen atom and optionally substituted by NR&#x2032;R&#x2033; as defined above or Ris Calkoxy substituted by NR&#x2032;R&#x2033; as defined above; Ris hydrogen or Calkyl; Ris hydrogen, Calkyl, Calkenyl, Calkynyl, Ccycloalkyl, aryl or aryl Calkyl; Ris hydrogen, Calkyl, Calkenyl, Calkynyl, Ccycloalkyl, aryl, aryl Calkyl or Calkoxycarbonyl; or Rand R, together with the nitrogen atom to which they are attached, form a C-Cmono- or bicyclic saturated ring; X and Y are independently chosen from hydrogen, hydroxy, nitro, amino, cyano, CF, halogen and Calkyl; or a pharmaceutically acceptable salt thereof; as NK-2/NK-3 ligands for treating schizophrenia, COPD, asthma or irritable bowel syndrome. 

Substituted quinoline-4-carboxylic hydrazides as NK-2/NK-3 receptor ligands

The compounds of formula I: inhibit gamma secretase and hence are of utility in the treatment or prevention of Alzheimer's Disease.

Pyrazole derivatives as gamma-secretase inhibitors useful in the treatment of Alzheimer's disease

A class of imidazo[1,2][1,2,4]triazine derivatives, substituted at the 7-position by an optionally substituted five-membered or six-membered heteroaromatic ring, being selective ligands for GABAreceptors, in particular having good affinity for the &#x3b1;2 and/or &#x3b1;3 and/or &#x3b1;5 subunit thereof, are accordingly of benefit in the treatment and/or prevention of adverse conditions of the central nervous system, including anxiety, convulsions and cognitive disorders.

Imidazo-triazine derivatives as ligands for gaba receptors

Growing community of inventors

Puckeridge, United Kingdom

Mark Stewart Chambers